In the manufacturing of peptide therapeutics and high-standard biologics, drug safety and cross-contamination control serve as the primary metrics for evaluating a peptide factory's compliance. Due to the inherent characteristics of peptide molecules—such as their susceptibility to degradation, strong adsorption properties, and potential biological activities—GMP (Good Manufacturing Practice) compliant peptide factories must adhere to exceptionally stringent technical specifications regarding equipment contamination prevention and Clean-in-Place (CIP) validation.

In the development lifecycle of peptide therapeutics, transitioning from milligram-scale laboratory synthesis to ton-scale commercial mass production in a peptide factory is a journey filled with strict technical challenges.

With the growing demand for peptide therapeutics and macromolecular biomaterials, the large-scale manufacturing of long-chain peptides has become a core competency for modern peptide factories. However, as the amino acid chain extends, steric hindrance increases significantly, slowing down the condensation reaction.